SCHEMBL204704

SCHEMBL204704

NC(=O)C(S)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.53
SLC1A2 P43004 2/20 0.53
SLC1A1 P43005 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
PARP10 Q53GL7 1/20 0.45
EPHX1 P07099 1/20 0.44
ALDH1A1 P00352 3/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26963671 0.81 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL376695 0.81 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL18381513 0.81 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL6567345 0.81 SLC1A3 (0.56) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL18925989 0.79 SLC1A1 (0.59) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL27849070 0.78 SLC1A1 (0.53) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL7977999 0.76 SLC1A3 (0.60) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL6740564 0.76 KMT2A (0.51) SLC1A3SLC1A2SLC1A1KMT2AMEN1
Carbamic Acid SCHEMBL27457276 0.76 SLC1A3 (0.54) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL7900106 0.75 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
US-20120122918-A1 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122918-A1 ANTIBACTERIAL AGENTS ALK, ROS1, ARG1 SLC1A3 4543/4885SLC1A2 4438/4885SLC1A1 4231/4885
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 SLC1A3 3429/4885SLC1A2 3565/4885SLC1A1 2592/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 SLC1A3 4464/4885SLC1A2 4262/4885SLC1A1 4050/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 SLC1A3 3429/4885SLC1A2 3565/4885SLC1A1 2592/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 SLC1A3 3429/4885SLC1A2 3565/4885SLC1A1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.